PHILADELPHIA, July 20, 201six /PRNewswire/ — GSK [LSE/NYSE: GSK] announced today it has actually begun shipping quadrivalent vaccine doses to US healthcare providers, complying with licensing and lot-release approval from the US Meals and Drug Administration’s (FDA) Focus for Biologics Evaluation and Research. It is the very first company to ship quadrivalent vaccine for the 2016-17 flu season.
The US Centers for Health problem Manage and Prevention (CDC) recommends flu vaccination as the single ideal measure for flu prevention. The CDC has actually a book recommendation for Americans over the age of 6 months to get hold of a flu vaccination each year as the very first and crucial step in protecting versus this disease.1,2 GSK’s flu vaccines are indicated for usage in persons three years and older.
“Our target is to be a reliable partner in the annual flu immunization campaign by creating and manufacturing higher quality quadrivalent influenza vaccines for the US population,” said Patrick Desbiens, Senior Vice President, US Vaccines. “This year we introduced Brand-new functionality to our eCommerce platform, www.GSKDirect.com, to enable those that stock and administer our vaccines to further accelerate delivery of their flu vaccines as soon as they order directly from us. We believe this enhancement supports healthcare providers by aiding to guarantee that their patients have actually access to the vaccines they need.”
Two various selections of the four-strain vaccines will certainly be available to customers. FLULAVAL® QUADRIVALENT comes in a 5-mL, multidose vial containing 10 doses (0.5mL each), while FLUARIX® QUADRIVALENT comes in a 0.5-mL, single-dose, prefilled syringe.
GSK expects to supply up to 40 million doses across the 2 vaccines for the US market in the 2016-17 season. One hundred percent of GSK supply is quadrivalent doses.
Quadrivalent vaccines are created to advice protect versus two various types of “A” flu strains and two types of “B” flu strains. Influenza A and Influenza B are the viruses that spread between individuals and can easily trigger mild to serious illness, leading to seasonal flu. Most flu activity in the US occurs from October-May, and commonly peaks in the US between December-February. According to the CDC, each year around five to twenty percent of individuals in the US get hold of the flu and Much more compared to 200,000 individuals are hospitalized for flu-related complications.3,4,5
For this year’s flu season, the Globe healthiness Organization (WHO) and FDA’s Vaccines and Related Blood Products Advisory Committee recommended including the A/California/7/2009 (H1N1)pdm09-enjoy virus, A/Hong Kong/4801/2014 (H3N2)-enjoy virus, and B/Brisbane/60/2008-enjoy virus (B/Victoria lineage), along with the addition of B/Phuket/3073/2013-enjoy virus (B/Yamagata lineage), for the quadrivalent vaccine.6,7
For Much more general short article concerning the flu, visit ChooseMoreChooseFour.com.
About GSK flu vaccine manufacturing
FLUARIX® QUADRIVALENT is manufactured in Dresden, Germany. FLULAVAL® QUADRIVALENT is manufactured in Ste-Foy, Quebec, Canada.
The complying with crucial Safety short article is based on the Highlights section of the Prescribing short article for FLULAVAL® QUADRIVALENT (Influenza Vaccine) and FLUARIX® QUADRIVALENT (Influenza Vaccine). Please consult the full Prescribing short article for all of the labeled safety short article for FLULAVAL® QUADRIVALENT and FLUARIX® QUADRIVALENT.
Professional Indication(s) for FLULAVAL® QUADRIVALENT (Influenza Vaccine) and FLUARIX® QUADRIVALENT (InfluenzaVaccine)
Indication for FLULAVAL® QUADRIVALENT
FLULAVAL® QUADRIVALENT is a vaccine indicated for energetic immunization for the prevention of Health problem caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLULAVAL® QUADRIVALENT is approved for usage in persons 3 years of age and older.
Indication for FLUARIX® QUADRIVALENT
FLUARIX® QUADRIVALENT is a vaccine indicated for energetic immunization for the prevention of Health problem caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUARIX® QUADRIVALENT is approved for usage in persons 3 years of age and older.
Combined crucial Safety short article for FluLaval® Quadrivalent (Influenza Vaccine) and Fluarix® Quadrivalent (InfluenzaVaccine)
- Do not administer FLULAVAL® QUADRIVALENT or FLUARIX® QUADRIVALENT to anyone along with known serious allergic reactions (anaphylaxis) to any sort of component of the vaccine, including egg protein, or a life‐threatening reaction to previous administration of any sort of influenza vaccine
- If Guillain-Barré syndrome has actually occurred within six weeks of receipt of a prior influenza vaccine, the decision to offer FLULAVAL® QUADRIVALENT or FLUARIX® QUADRIVALENT must be based on careful consideration of the potential rewards and risks
- Syncope (fainting) can easily occur in association along with administration of injectable vaccines. Procedures must be in place to stay away from falling injury and to restore cerebral perfusion complying with syncope
- If FLULAVAL® QUADRIVALENT or FLUARIX® QUADRIVALENT is administered to immunosuppressed persons, including people receiving immunosuppressive therapy, the immune response might be reduced compared to in immunocompetent persons
- In clinical trials along with FLULAVAL® QUADRIVALENT, the most common solicited local side reaction in adults was pain. The most common solicited systemic side reactions in adults were muscle aches, headache, fatigue, and arthralgia. In kids 3 through 17 years of age, the most common solicited local side reaction was pain. In kids 3 through 4 years of age, the most common solicited systemic side reactions were irritability, drowsiness, and loss of appetite. In kids five through 17 years of age, the most common solicited systemic side reactions were muscle aches, fatigue, headache, arthralgia, and gastrointestinal symptoms. (See side Reactions section of the Prescribing short article for FLULAVAL® QUADRIVALENT for others potential side reactions and events)
- In clinical trials along with FLUARIX® QUADRIVALENT, the most common injection site side reaction in adults was pain. The most common systemic side reactions in adults were muscle aches, headache, and fatigue. In kids 3 through 17 years of age, injection site side reactions were pain, redness, and swelling. In kids 3 through 5 years of age, the most common systemic side reactions were drowsiness, irritability, and loss of appetite. In kids six through 17 years of age, the most common systemic side reactions were fatigue, muscle aches, headache, arthralgia, and gastrointestinal symptoms. (See side Reactions section of the Prescribing short article for FLUARIX® QUADRIVALENT for others potential side reactions and events)
- Vaccination along with FLULAVAL® QUADRIVALENT or FLUARIX® QUADRIVALENT Could not result in protection in all of vaccine recipients
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to boosting the quality of human life by enabling individuals to do more, feel much better and live longer. For further short article please visit www.gsk.com.
|
GSK enquiries: |
|||
|
UK Media enquiries: |
David Mawdsley |
+44 (0) twenty 8047 5502 |
(London) |
|
Simon Steel |
+44 (0) twenty 8047 5502 |
(London) |
|
|
David Daley |
+44 (0) twenty 8047 5502 |
(London) |
|
|
Catherine Hartley |
+44 (0) twenty 8047 5502 |
(London) |
|
|
Claire Brough |
+44 (0) twenty 8047 5502 |
(London) |
|
|
US Media enquiries: |
Sarah Alspach |
+1 202 71five 1048 |
(Washington, DC) |
|
Sarah Spencer |
+1 21five 751 3335 |
(Philadelphia) |
|
|
Mary Anne Rhyne |
+1 919 483 0492 |
(North Carolina) |
|
|
Jenni Ligday |
+1 202 71five 1049 |
(Washington, DC) |
|
|
Karen Hagens |
+1 919 483 2863 |
(North Carolina) |
|
|
Gwynne Oosterbaan |
+1 21five 751 7468 |
(Philadelphia) |
|
|
Analyst/Investor enquiries: |
Ziba Shamsi |
+44 (0) twenty 8047 5543 |
(London) |
|
Tom Curry |
+ 1 21five 751 5419 |
(Philadelphia) |
|
|
Gary Davies |
+44 (0) twenty 8047 5503 |
(London) |
|
|
James Dodwell |
+44 (0) twenty 8047 2406 |
(London) |
|
|
Jeff McLaughlin |
+1 21five 751 7002 |
(Philadelphia) |
|
Cautionary statement about forward-looking statements |
|
Registered in England & Wales: No. 3888792 |
|
Registered Office: 980 Terrific West Road Brentford, Middlesex TW8 9GS |
To view the original version on PR Newswire, visit:http://ift.tt/29WrNh2
from Influenza – NewsBlog http://ift.tt/2a8WKgO
